🎉 M&A multiples are live!
Check it out!

Collegium Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Collegium Pharmaceutical and other public comps.

See Collegium Pharmaceutical Valuation Multiples

Collegium Pharmaceutical Overview

About Collegium Pharmaceutical

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.


Founded

2002

HQ

United States of America
Employees

197

Financials

LTM Revenue $642M

LTM EBITDA $403M

EV

$1.7B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Collegium Pharmaceutical Financials

Collegium Pharmaceutical has a last 12-month revenue of $642M and a last 12-month EBITDA of $403M.

In the most recent fiscal year, Collegium Pharmaceutical achieved revenue of $567M and an EBITDA of $308M.

Collegium Pharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Collegium Pharmaceutical valuation multiples based on analyst estimates

Collegium Pharmaceutical P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $464M $567M $629M $642M XXX
Gross Profit $151M $209M $326M XXX XXX
Gross Margin 32% 37% 52% XXX XXX
EBITDA $173M $308M $399M $403M XXX
EBITDA Margin 37% 54% 63% 63% XXX
Net Profit $71.5M -$25.0M $48.2M XXX XXX
Net Margin 15% -4% 8% XXX XXX
Net Debt $63.6M $527M $428M XXX XXX

Financial data powered by Morningstar, Inc.

Collegium Pharmaceutical Stock Performance

As of February 10, 2025, Collegium Pharmaceutical's stock price is $31.

Collegium Pharmaceutical has current market cap of $994M, and EV of $1.7B.

See Collegium Pharmaceutical trading valuation data

Collegium Pharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.7B $994M XXX XXX XXX XXX $6.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Collegium Pharmaceutical Valuation Multiples

As of February 10, 2025, Collegium Pharmaceutical has market cap of $994M and EV of $1.7B.

Collegium Pharmaceutical's trades at 2.7x LTM EV/Revenue multiple, and 4.3x LTM EBITDA.

Analysts estimate Collegium Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Collegium Pharmaceutical and 10K+ public comps

Collegium Pharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.7B XXX XXX XXX
EV/Revenue 2.8x XXX XXX XXX
EV/EBITDA 4.4x XXX XXX XXX
P/E 4.0x XXX XXX XXX
P/E/Growth 0.5x XXX XXX XXX
EV/FCF 8.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Collegium Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Collegium Pharmaceutical Valuation Multiples

Collegium Pharmaceutical's NTM/LTM revenue growth is 16%

Collegium Pharmaceutical's revenue per employee for the last fiscal year averaged $2.9M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Collegium Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Collegium Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Collegium Pharmaceutical and other 10K+ public comps

Collegium Pharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 11% XXX XXX XXX XXX
EBITDA Margin 63% XXX XXX XXX XXX
EBITDA Growth 29% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 79% XXX XXX XXX XXX
Revenue per Employee $2.9M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 28% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Collegium Pharmaceutical Public Comps

See valuation multiples for Collegium Pharmaceutical public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Collegium Pharmaceutical M&A and Investment Activity

Collegium Pharmaceutical acquired  XXX companies to date.

Last acquisition by Collegium Pharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Collegium Pharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Collegium Pharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Collegium Pharmaceutical

When was Collegium Pharmaceutical founded? Collegium Pharmaceutical was founded in 2002.
Where is Collegium Pharmaceutical headquartered? Collegium Pharmaceutical is headquartered in United States of America.
How many employees does Collegium Pharmaceutical have? As of today, Collegium Pharmaceutical has 197 employees.
Who is the CEO of Collegium Pharmaceutical? Collegium Pharmaceutical's CEO is Mr. Vikram Karnani.
Is Collegium Pharmaceutical publicy listed? Yes, Collegium Pharmaceutical is a public company listed on NAS.
What is the stock symbol of Collegium Pharmaceutical? Collegium Pharmaceutical trades under COLL ticker.
When did Collegium Pharmaceutical go public? Collegium Pharmaceutical went public in 2015.
Who are competitors of Collegium Pharmaceutical? Similar companies to Collegium Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Collegium Pharmaceutical? Collegium Pharmaceutical's current market cap is $994M
What is the current revenue of Collegium Pharmaceutical? Collegium Pharmaceutical's last 12-month revenue is $642M.
What is the current EBITDA of Collegium Pharmaceutical? Collegium Pharmaceutical's last 12-month EBITDA is $403M.
What is the current EV/Revenue multiple of Collegium Pharmaceutical? Current revenue multiple of Collegium Pharmaceutical is 2.7x.
What is the current EV/EBITDA multiple of Collegium Pharmaceutical? Current EBITDA multiple of Collegium Pharmaceutical is 4.3x.
What is the current revenue growth of Collegium Pharmaceutical? Collegium Pharmaceutical revenue growth between 2023 and 2024 was 11%.
Is Collegium Pharmaceutical profitable? Yes, Collegium Pharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.